Na, Young-Soon <br/><br/>
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Aug 2011 
 - 389-98 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-010-1495-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Apoptosis--drug effects<br/>Camptothecin--administration & dosage<br/>Cell Proliferation--drug effects<br/>Colonic Neoplasms--drug therapy<br/>Drug Synergism<br/>Female<br/>HCT116 Cells<br/>HT29 Cells<br/>Histone Deacetylase Inhibitors--administration & dosage<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Irinotecan<br/>Mice<br/>Mice, Nude<br/>Prodrugs--administration & dosage<br/>Random Allocation<br/>Sulfonamides<br/>Topoisomerase I Inhibitors--administration & dosage<br/>Tumor Burden--drug effects<br/>Whole Body Imaging<br/>Xenograft Model Antitumor Assays